🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Neoplastic Syndromes, Hereditary

Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer NCT06088030Phase 21 site📍 Guangzhou Yang Li · Tests: Arsenic trioxide Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a1 site📍 Sioux Falls Sanford Health HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas NCT05331105Phase 21 site📍 Shanghai Shanghai Kechow Pharma, Inc. · Tests: HL-085 Duodenal Polyposis Classification in FAP NCT07199127n/a2 sites📍 Milan📍 Milan Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Tests: DRACO PTEN Hamartoma Tumor Syndrome Pediatric Patient Registry NCT06462430n/a1 site📍 Istanbul Yale University Natural History Study of Parathyroid Disorders NCT04969926n/a1 site📍 Bethesda National Institute of Diabetes and Digestive and Kidney Dis… Study of the Disease Process of Lymphangioleiomyomatosis NCT00001465n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) · Tests: Toshibia Aquilion One CT Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas NCT05253131Phase 21 site📍 Birmingham University of Alabama at Birmingham · Tests: Selumetinib + ZEN-3694 ± Durvalumab Acute Effects of Ketone Monoester Co-ingestion With Dietary Protein on Whole-body Phenylalanine Oxidation, Phenylalanine Retention, and Myofibrillar Protein Breakdown Following Resistance Exercise in Young Males. NCT07884539NA1 site📍 Montreal McGill University · Tests: Ketone Monoester + Dietary Protein (KET+PRO), Dietary Protein (PRO), Resistance Exercise Glioma Developmental and HyperActive Ras Tumor (DHART) Board NCT05489783n/a7 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center Cancer Predisposition Testing by Family-based Whole-genome Sequencing (WGS) in Every Child With Newly Diagnosed Cancer NCT04903782n/a3 sites📍 Newcastle📍 Sydney📍 Sydney Sydney Children's Hospitals Network · Tests: Family-based whole genome sequencing Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1 NCT07102394Phase 11 site📍 Baltimore Johns Hopkins University · Tests: Imlygic Treatment With Full-spectrum Cannabis Extract of Refractory Epilepsy Associated With Tuberous Sclerosis Complex (TSC) NCT07403266Phase 31 site📍 Madrid Oils4Cure · Tests: YCJ-01 Full Spectrum cannbis Extract, Placebo Mirdametinib in Patients With Advanced NF1-mutant Melanoma NCT07237100Phase 21 site📍 San Francisco Kevin Kim, MD · Tests: Mirdametinib Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment NCT05562778NA4 sites📍 Brooklyn📍 New York📍 New York Weill Medical College of Cornell University · Tests: Chatbot Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas NCT06502171Phase 18 sites📍 Birmingham📍 Los Angeles📍 Washington D.C. Girish Dhall, MD · Tests: Cabozantinib Oral Tablet, Selumetinib Oral Capsule A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1) NCT06507748NA2 sites📍 Washington D.C.📍 Bethesda National Cancer Institute (NCI) · Tests: AlgometRx Nociometer(R) Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) NCT05552755Phase 1, Phase 217 sites📍 Scottsdale📍 Tucson📍 San Diego Recursion Pharmaceuticals Inc. · Tests: REC-4881, Placebo Video Capsule Examination in Patients With Lynch Syndrome NCT06712095NA1 site📍 London Royal Marsden NHS Foundation Trust · Tests: Video capsule investigation Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome NCT04920149Phase 28 sites📍 Aalborg📍 Hvidovre📍 Gothenburg Ann-Sofie Backman · Tests: Mesalamine, Placebo Implementation of Population Cancer Genetic Services in Federally Qualified Health Centers (FQHC) NCT05664867NA1 site📍 Chicago University of Illinois Chicago · Tests: Mainstream Genetic Testing Model, Enhanced Standard of Care Model Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors NCT07584499Phase 11 site📍 Guangzhou Sun Yat-sen University · Tests: Becotatug Vedotin Improving HIV Testing, Linkage, and Retention in Care for Men Through U=U Messaging NCT05602376NA2 sites📍 East London📍 Cape Town Desmond Tutu HIV Foundation · Tests: U=U testing messaging scripts, U=U adherence messaging scripts Clinical and Genetic Studies of Li-Fraumeni Syndrome NCT01443468n/a2 sites📍 Bethesda📍 Bethesda National Cancer Institute (NCI) Treatment of Newly Diagnosed Patient's With Wilm's Tumor Requiring Abdominal Radiation Delivered With Proton Beam Irradiation NCT04968990Phase 21 site📍 Memphis St. Jude Children's Research Hospital · Tests: Proton Beam Radiation (PBRT), DD-4A Chemotherapy Regimen, Complete Surgical Resection, Surgical Resection, Partial Neph… Registry of Multiple Osteochondromas NCT04133285n/a1 site📍 Bologna Luca Sangiorgi A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 NCT06541847Phase 214 sites📍 Birmingham📍 Los Angeles📍 Palo Alto Healx Limited · Tests: HLX-1502 GROWing Up With Rare GENEtic Syndromes NCT04463316n/a1 site📍 Rotterdam dr. Laura C. G. de Graaff-Herder · Tests: Retrospective file studies Study and Follow-up of Multiple Endocrine Neoplasia Type 1 NCT03348501n/a1 site📍 Dijon Centre Hospitalier Universitaire Dijon · Tests: survey for long-term follow-up of the disease
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy